Why international growth in the life sciences sector requires businesses to understand not only the commercial opportunity, but the political priorities, institutional relationships and policy environments shaping the markets they enter.
A life sciences company entering a new international market will typically arrive with a carefully developed commercial strategy - it will have assessed demand, identified potential partners, considered distribution arrangements and established its regulatory pathway. It may have invested considerable time and capital in understanding the competitive landscape.
Yet one of the most consequential aspects of market entry can receive considerably less attention: the external environment in which the business will be expected to operate.
In life sciences, commercial success is often shaped by regulatory institutions, healthcare policy, reimbursement frameworks, public procurement, clinical priorities, professional bodies, patient organisations and the political decisions that influence how healthcare systems allocate resources. These are not peripheral considerations, but are a part of the market itself.
A company can have an effective product, strong clinical evidence and a compelling commercial proposition, but still encounter significant barriers if it does not understand how decisions are made, who influences them and what priorities shape the institutions responsible for delivering healthcare.
Every country has its own healthcare architecture, regulatory arrangements and political priorities. Even where markets share broad principles or regulatory standards, the practical routes to adoption, funding and procurement can differ considerably.
A new entrant may need to navigate relationships between health ministries, regulatory authorities, national health services, regional healthcare bodies, reimbursement agencies, procurement organisations and professional associations. The influence of each institution will depend on the country, the product and the route through which it reaches patients.
It is equally important to understand the institutional culture surrounding it. Which organisations shape policy? Where does decision-making authority sit? Which stakeholders influence clinical adoption? What pressures are affecting healthcare budgets? How are emerging technologies being viewed by policymakers? Are there domestic industrial priorities, political sensitivities or public concerns that could affect the reception of an international company?
These questions help establish a more realistic picture of the operating environment, and for an international business, this is where public affairs becomes a strategic function rather than a reactive communications activity.
Public affairs is sometimes understood too narrowly as government relations or lobbying, but in practice, its value is considerably broader.
It is the discipline of understanding how public policy, institutional relationships, stakeholder interests and political developments affect an organisation's ability to operate and achieve its objectives. For a life sciences company entering a new country, that means developing an informed understanding of the environment before commercial decisions become difficult or expensive to change.
This begins with stakeholder intelligence: identifying the institutions, policymakers, professional bodies, patient organisations, healthcare leaders and other actors relevant to the company's market-entry objectives. It requires understanding not only who they are, but their respective responsibilities, interests, influence and perspectives.
It also requires policy and political analysis - changes in government priorities, healthcare funding, industrial strategy, regulation or public procurement can alter the conditions in which a business operates. Understanding these developments early can help leadership teams anticipate challenges, identify opportunities and make better-informed decisions.
The objective is to establish the knowledge and credibility required to engage constructively with the people and institutions shaping the market.
International expansion also presents a question of legitimacy.
A business may have an established reputation in its home market, but that reputation does not automatically transfer across borders where new stakeholders may have limited knowledge of the organisation, its research, its contribution or its intentions.
In healthcare, where decisions can have direct consequences for patients, public trust and institutional confidence are particularly important. A company must be able to explain why its presence matters to the market it intends to serve and that could involve demonstrating its contribution to research and development, clinical outcomes, local employment, skills, healthcare capacity or wider economic priorities.
The way that proposition is communicated is critical. A narrative developed for a UK audience may not translate effectively into Singapore, Germany, the United States or the Gulf. Different healthcare systems, political priorities, cultural expectations and stakeholder relationships require different approaches, but this does not mean abandoning a company's international identity, it means understanding how its value can be articulated credibly within a local context.
Local partnerships, informed stakeholder engagement and a considered communications strategy can all contribute to that process, so can an appreciation of the issues that matter to patients, healthcare professionals and policymakers in the market concerned.
One of the risks of treating public affairs as a later-stage activity is that organisations can find themselves responding to circumstances they could have anticipated, or even prepared for.
A procurement process may be shaped by priorities that were not considered during the initial market assessment, a proposed product launch may encounter public or political sensitivities, a change in government may alter the emphasis placed on domestic manufacturing, healthcare expenditure or access to innovative treatments, and a stakeholder relationship that appeared straightforward may prove more complicated once the institutional context becomes clear.
Not every development can be predicted, and no amount of analysis removes commercial or political uncertainty, but organisations can improve their preparedness by establishing a structured understanding of the environment before committing significant resources. This means integrating public affairs, stakeholder intelligence, reputation and communications into the market-entry process versus treating them as separate workstreams.
For leadership teams, the practical questions are straightforward: What could prevent adoption? Who has the authority to make the relevant decisions? What interests or concerns will shape those decisions? Where might political or reputational exposure arise? What relationships need to be established before the organisation enters the market?
These questions belong in the boardroom, not within the communications department.
This is where the distinction between gathering information and developing intelligence becomes important. Market research can establish the size of an opportunity, regulatory advice can explain the applicable requirements, and commercial analysis can identify potential routes to revenue. Each has an essential role, but leadership teams also need to understand how the political, institutional and stakeholder environment interacts with those considerations.
That requires an integrated approach combining external environment analysis, stakeholder mapping, policy monitoring, political intelligence, reputation assessment and strategic communications.
For businesses considering international expansion, this means looking beyond the immediate communications requirements of market entry, it means understanding the relationships, institutions, narratives and developments that could shape the organisation's longer-term prospects.
It is also important to recognise that international markets require local knowledge. Effective advice depends on combining strategic oversight with trusted regional expertise, including specialist legal, regulatory and market-access partners where appropriate. No external adviser can substitute for that expertise; the value lies in bringing the different perspectives together.
The most effective market-entry strategies are therefore not developed in isolation from public affairs, they recognise that commercial opportunity, political context, institutional relationships and public confidence are interconnected, and understanding that system should not be an optional addition to that strategy, but part of the strategy itself.